Antibody Therapy for Polybacterial Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies are inadequate for effectively preventing and treating polybacterial infections, particularly those involving Staphylococcus aureus and Pseudomonas aeruginosa, due to increasing multidrug resistance and the complexity of polymicrobial infections.
Innovation Solution
Development of antibodies or antigen-binding fragments that specifically bind to Staphylococcus aureus alpha toxin, potentiating the immune response and inhibiting the growth of co-isolated bacteria, administered alone or in combination with other anti-bacterial agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat bacterial infections, then treatment effectiveness is maintained for single-bacterium infections, but treatment failure occurs for polybacterial infections due to multidrug resistance
Solution Approach 1:
The patent develops antibodies with broad-spectrum activity that can recognize and bind to multiple bacterial species simultaneously. The antibody composition includes antibodies against S. aureus and antibodies against Gram-negative bacteria, creating a universal treatment approach that addresses polybacterial infections with a single therapeutic agent rather than requiring multiple separate treatments.
2Adaptability or versatility
If combination antibiotic therapy is used to address polybacterial infections, then coverage of multiple bacteria is improved, but treatment complexity and risk of further resistance increase
Solution Approach 1:
The patent combines multiple antibacterial activities into a single antibody composition formulation. The composition includes antibodies against S. aureus and antibodies against Gram-negative bacteria in the same pharmaceutical preparation, allowing simultaneous treatment of multiple bacterial pathogens through a single administration rather than requiring separate combination therapies.
3Adaptability or versatility
If broad-spectrum antibiotics are used to cover multiple bacteria, then initial treatment coverage is improved, but development of multidrug resistance accelerates
Solution Approach 1:
The patent uses antibodies as intermediary agents that provide targeted immunological recognition and neutralization of bacterial pathogens. Rather than using antibiotics that exert broad chemical pressure on all bacteria, the antibodies serve as specific mediators that bind to bacterial antigens, activating the immune system's natural defense mechanisms and reducing selective pressure for resistance development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies significantly reduce the colony-forming units of Pseudomonas aeruginosa and Staphylococcus aureus, improving survival rates and decreasing mortality in mouse models of polybacterial infections, demonstrating efficacy in preventing and treating ocular, lung, burn, and skin infections.
Implementation Method 1
The antibody or antigen-binding fragment thereof specifically binds to a S. aureus antigen, and the S. aureus antigen is alpha toxin
Data Source
Figure 1~1B
Figure 2~2B
Figure 3
AI summary
Provided herein are methods of preventing and treating polybacterial infections comprising administering an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope produced by at least one of the bacterium in the polybacterial infection. For example, an antibody that specifically binds to Staphylococcus aureus alpha toxin can be administered to a patient with a polybacterial infection comprising Staphylococcus aureus and Pseudomonas aeruginosa to inhibit the growth of Pseudomonas aeruginosa.